MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC
Status:
Completed
Trial end date:
2017-01-04
Target enrollment:
Participant gender:
Summary
The first testing of TargomiRs in the human setting: dose-finding studies in patients with
recurrent malignant pleural mesothelioma and non-small cell lung cancer